 DURHAM, N.C.--BUSINESS WIRE--Aerie Pharmaceuticals, Inc. NASDAQ: AERI, an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 dexamethasone intravitreal implant Phase 2 clinical trial in patients with macular edema due to retinal vein occlusion will be presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists in San Antonio, Texas. The presentation entitled Phase 2 Study of Two Formulations of AR-1105 in Macular Ede 